Combination of rosuvastatin and probucol inhibits MMP-9 expression via upregulation of miR-497 in cultured HUVECs and apoE knockout mice

详细信息    查看全文

• 作者：Yuan-yuan Wang ; Hui Li ; Xing-hua Wang ; Meng Yuan…
• 关键词：Rosuvastatin ; Probucol ; MicroRNAs ; Matrix metalloproteinases
• 刊名：Journal of Thrombosis and Thrombolysis
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：41
• 期：4
• 页码：592-605
• 全文大小：12,058 KB
• 参考文献：1.Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(11):e442CrossRef PubMed PubMedCentral
  2.Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340(2):115–126CrossRef PubMed
  3.Montecucco F, Lenglet S, Gayet-Ageron A, Bertolotto M, Pelli G, Palombo D, Pane B, Spinella G, Steffens S, Raffaghello L, Pistoia V, Ottonello L, Pende A, Dallegri F, Mach F (2010) Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 41(7):1394–1404CrossRef PubMed
  4.Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB, Thomas AC (2009) Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost 101(6):1006–1011PubMed PubMedCentral
  5.Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 375(9709):132–140CrossRef
  6.Canouï-Poitrine F, Luc G, Mallat Z, Machez E, Bingham A, Ferrieres J, Ruidavets JB, Montaye M, Yarnell J, Haas B, Arveiler D, Morange P, Kee F, Evans A, Amouyel P, Ducimetiere P, Empana JP, PRIME Study Group (2011) Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology. 77(12):1165–1673CrossRef PubMed PubMedCentral
  7.Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P (1999) Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99(19):2503–2509CrossRef PubMed
  8.Johnson JL, Devel L, Czarny B, George SJ, Jackson CL, Rogakos V, Beau F, Yiotakis A, Newby AC, Dive V (2011) A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 31(3):528–535CrossRef PubMed PubMedCentral
  9.Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ (2007) Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 45(4):849–857CrossRef PubMed
  10.Brown DL, Hibbs MS, Kearney M, Isner JM (1997) Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. Am J Cardiol 79(7):878–882CrossRef PubMed
  11.Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75(1):50–83CrossRef PubMed PubMedCentral
  12.Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S, Mach F (2009) Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatol (Oxf) 48(3):233–242CrossRef
  13.Kim J, Min JK, Park JA, Doh HJ, Choi YS, Rho J, Kim YM, Kwon YG (2010) Receptor activator of nuclear factor kappaB ligand is a novel inducer of tissue factor in macrophages. Circ Res 107(7):871–876CrossRef PubMed
  14.Quercioli A, Mach F, Bertolotto M, Lenglet S, Vuilleumier N, Galan K, Pagano S, Braunersreuther V, Pelli G, Pistoia V, Bianchi G, Cittadini G, Viviani GL, Pende A, Roux-Lombard P, Thomas A, Staub C, Ratib O, Dallegri F, Schindler TH, Montecucco F (2012) Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost 107(1):124–139CrossRef PubMed
  15.Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V, Pelli G, Kovari E, Pane B, Spinella G, Pende A, Palombo D, Dallegri F, Mach F, Roux-Lombard P (2011) Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 32(4):412–421CrossRef PubMed
  16.Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127–155CrossRef PubMed
  17.Cobb MH, Goldsmith EJ (1995) How MAP kinases are regulated. J Biol Chem 270(25):14843–14846CrossRef PubMed
  18.Cho A, Graves J, Reidy MA (2000) Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20(12):2527–2532CrossRef PubMed
  19.Khan KM, Falcone DJ, Kraemer R (2002) Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. J Biol Chem 277(3):2353–2359CrossRef PubMed
  20.Ohshima S, Fujimoto S, Petrov A, Nakagami H, Haider N, Zhou J, Tahara N, Osako MK, Fujimoto A, Zhu J, Murohara T, Edwards DS, Narula N, Wong ND, Chandrashekhar Y, Morishita R, Narula J (2010) Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging. J Am Coll Cardiol 55(12):1240–1249CrossRef PubMed
  21.Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists’ (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278CrossRef PubMed
  22.Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376(9753):1670–1681CrossRef
  23.Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C (1987) Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84(16):5928–5931CrossRef PubMed PubMedCentral
  24.Daugherty A, Zweifel BS, Schonfeld G (1989) Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol 98(2):612–618CrossRef PubMed PubMedCentral
  25.Niimi M, Keyamura Y, Nozako M, Koyama T, Kohashi M, Yasufuku R, Yoshikawa T, Fan J (2013) Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. Lipids Health Dis. 4(12):166CrossRef
  26.Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A, Daida H (2012) Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis. 220(2):463–469CrossRef PubMed
  27.Kesäniemi YA, Grundy SM (1984) Influence of probucol on cholesterol and lipoprotein metabolism in man. J Lipid Res 25(8):780–790PubMed
  28.Siveski-Iliskovic N, Kaul N, Singal PK (1994) Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89(6):2829–2835CrossRef PubMed
  29.Bräsen JH, Koenig K, Bach H, Kontush A, Heinle H, Witting PK, Ylä-Herttuala S, Stocker R, Beisiegel U (2002) Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis. 163(2):249–259CrossRef PubMed
  30.Fruebis J, Gonzalez V, Silvestre M, Palinski W (1997) Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 17(7):1289–1302CrossRef PubMed
  31.Wu TC, Chen YH, Leu HB, Chen YL, Lin FY, Lin SJ, Chen JW (2007) Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. Free Radic Biol Med 43(11):1508–1522CrossRef PubMed
  32.Li S, Liang J, Niimi M, Bilal Waqar A, Kang D, Koike T, Wang Y, Shiomi M, Fan J (2014) Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. J Atheroscler Thromb 21(7):648–658CrossRef PubMed
  33.Kim VN (2005) Small RNAs: classification, biogenesis, and function. Mol Cells 19(1):1–15CrossRef PubMed
  34.Petersen CP, Bordeleau ME, Pelletier J, Sharp PA (2006) Short RNAs repress translation after initiation in mammalian cells. Mol Cell 21(4):533–542CrossRef PubMed
  35.Cipollone F, Felicioni L, Sarzani R, Ucchino S, Spigonardo F, Mandolini C, Malatesta S, Bucci M, Mammarella C, Santovito D, de Lutiis F, Marchetti A, Mezzetti A, Buttitta F (2011) A unique microRNA signature associated with plaque instability in humans. Stroke 42(9):2556–2563CrossRef PubMed
  36.Raitoharju E, Lyytikäinen LP, Levula M, Oksala N, Mennander A, Tarkka M, Klopp N, Illig T, Kähönen M, Karhunen PJ, Laaksonen R, Lehtimäki T (2011) miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 219(1):211–217CrossRef PubMed
  37.Zheng D, Radziszewska A, Woo P (2012) MicroRNA 497 modulates interleukin 1 signalling via the MAPK/ERK pathway. FEBS Lett 586(23):4165–4172CrossRef PubMed
  38.Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK (2009) Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance? Int J Clin Pract 63(3):478–485CrossRef PubMed
  39.Saito Y, Yamada N, Shirai K, Sasaki J, Ebihara Y, Yanase T, Fox JC (2007) Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis 194(2):505–511CrossRef PubMed
  40.Caslake MJ, Stewart G, Day SP, Daly E, McTaggart F, Chapman MJ, Durrington P, Laggner P, Mackness M, Pears J, Packard CJ (2003) Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 171(2):245–253CrossRef PubMed
  41.McTaggart F, Jones P (2008) Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 22(4):321–338CrossRef PubMed PubMedCentral
  42.Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP (2009) Pleiotropic effects of statins–clinical evidence. Curr Pharm Des 15(5):479–489CrossRef PubMed
  43.Blum A, Shamburek R (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 203(2):325–330CrossRef PubMed
  44.Chen J, Li D, Schaefer RF, Mehta JL (2004) Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol 44(4):446–452CrossRef PubMed
  45.Satoh M, Tabuchi T, Minami Y, Takahashi Y, Itoh T, Nakamura M (2012) Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal. Immunobiology 217(5):533–539CrossRef PubMed
  46.Wu XD, Zeng K, Liu WL, Gao YG, Gong CS, Zhang CX, Chen YQ (2014) Effect of aerobic exercise on miRNA-TLR4 signaling in atherosclerosis. Int J Sports Med 35(4):344–350PubMed
  47.Liu RR, Li J, Gong JY, Kuang F, Liu JY, Zhang YS, Ma QL, Song CJ, Truax AD, Gao F, Yang K, Jin BQ, Chen LH (2015) MicroRNA-141 regulates the expression level of ICAM-1 on endothelium to decrease myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol:ajpheart-00290. [Epub ahead of print]
  48.Li X, Zeng Z, Li Q, Xu Q, Xie J, Hao H, Luo G, Liao W, Bin J, Huang X, Liao Y (2015) Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. Oncotarget 6(22):18829–18844CrossRef PubMed PubMedCentral
  49.Li Z, Lu J, Luo Y, Li S, Chen M (2014) High association between human circulating microRNA-497 and acute myocardial infarction. Sci World J 2014:931845
  50.Cai D, Jia Y, Lu J, Yuan M, Sui S, Song H, Zhao R (2014) Maternal dietary betaine supplementation modifies hepatic expression of cholesterol metabolic genes via epigenetic mechanisms in newborn piglets. Br J Nutr 112(9):1459–1468CrossRef PubMed
  51.Bräsen JH, Harsch M, Niendorf A (1998) Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet. Virchows Arch 432(6):557–562CrossRef PubMed
  52.Ge CJ, Lü SZ, Feng LX, Huo Y, Song XT, Chen X, Meng K, Yuan F (2012) Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion. Chin Med J (Engl). 125(14):2472–2476PubMed
  
• 作者单位：Yuan-yuan Wang (1)
  Hui Li (1)
  Xing-hua Wang (1)
  Meng Yuan (1)
  Guang-ping Li (1)
  
  1. Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Department of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 300211, People’s Republic of China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  Hematology
  
• 出版者：Springer Netherlands
• ISSN：1573-742X

文摘

This study deciphered the molecular mechanisms of the inhibition of MMP-9 expression using rosuvastatin in cultured human umbilical vein endothelial cells (HUVECs) and apoE knockout mice and whether the combination of rosuvastatin and probucol enhanced this effect. The role that microRNA (miR)-497 plays in the regulation of MMP-9 expression was evaluated in cultured HUVECs and apoE knockout mice using quantitative real-time reverse transcription polymerase chain reaction and Western blotting. First, TNFα significantly increased mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/ERK) signaling and MMP-9 levels, and the transfection of miR-497 prevented this increase. The converse results were obtained after miR-497 suppression. Second, the administration of rosuvastatin or the combination of two drugs decreased MAPK/ERK signaling and MMP-9 levels, and the suppression of miR-497 upregulated these levels. Third, the administration of rosuvastatin or the combination of two drugs increased miR-497 expression levels in the aortas of apoE knockout mice, but the levels of serum lipids and plaque areas decreased, which improved plaque components and decreased the MAPK/ERK signaling and MMP-9 levels. Finally, the combination of the two drugs was more effective than the use of rosuvastatin alone. Rosuvastatin inhibits MMP-9 expression by upregulating miR-497 in HUVECs and apoE knockout mice, and the combination of rosuvastatin and probucol enhances this effect.